Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 1:11 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–18 of 18 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: H3N2 Influenza Clear all

Conditions: Influenza
Interventions: DNA vaccine, TIV; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 131 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 4
States / cities: Decatur, Georgia • St Louis, Missouri • Cincinnati, Ohio + 1 more

Conditions: Influenza
Interventions: Influenza RG-A/Texas/71/2017 (H3N2) Challenge, Placebo; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Baltimore, Maryland • Durham, North Carolina

Conditions: Influenza
Interventions: A/Texas; Biological
Lead sponsor: Daniel Hoft, MD, PhD; Other
Eligibility: 18 Years to 45 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Influenza
Interventions: Influenza A/H3N2 variant Vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 211 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 4
States / cities: Decatur, Georgia • Iowa City, Iowa • Houston, Texas + 1 more

Conditions: Influenza
Interventions: Influenza Virus influenza A H3N2 strain; Biological
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 49 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Influenza, Influenza Immunisation
Interventions: Influenza Virus Monovalent A/H3N2/Bris 10 M2SR Live Vaccine, Placebo, Quadrivalent MDCK Inactivated Influenza Vaccine; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 9 Years to 17 Years
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Influenza A
Interventions: LD Sing2016 M2SR H3N2 influenza vaccine, MD Sing2016 M2SR H3N2 influenza vaccine, HD Sing2016 M2SR H3N2 influenza vaccine, LD Bris10 M2SR H3N2 influenza vaccine, Placebo; Biological · Other
Lead sponsor: FluGen Inc; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 206 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 4
States / cities: Hollywood, Florida • Lenexa, Kansas • Lexington, Kentucky + 1 more

Conditions: Influenza, Human
Interventions: aQIV or aTIV, QIV or TIV; Biological
Lead sponsor: Seqirus; Industry
Eligibility: 65 Years and older
Enrollment: 38,769 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 111
States / cities: Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 96 more

Conditions: Influenza Vaccine
Interventions: Cam2020 M2SR H3N2 influenza vaccine, Fluzone HD IIV, IN Placebo, IM Placebo; Biological · Other
Lead sponsor: FluGen Inc; Industry
Eligibility: 65 Years to 85 Years
Enrollment: 303 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 6
States / cities: Port Orange, Florida • Meridian, Idaho • Lenexa, Kansas + 3 more

Conditions: Influenza, Influenza, Human, Vaccine Reaction, Influenza A, Influenza Type B, Influenza A H1N1, Influenza A H3N2
Interventions: Influenza Vaccine Recipients; Biological
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 45 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Influenza Viral Infections
Interventions: Influenza A/Texas/71/2017 (H3N2), Sham placebo; Biological
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 46 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Influenza
Interventions: Live attenuated Influenza vaccine, Trivalent Influenza Vaccine, TIV followed by LAIV, LAIV followed by TIV; Biological
Lead sponsor: University of Rochester; Other
Eligibility: 2 Years to 9 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 2
States / cities: Lebanon, New Hampshire • Rochester, New York

Conditions: Influenza Vaccine
Interventions: Sing2016 M2SR H3N2 influenza vaccine, Placebo; Biological · Other
Lead sponsor: FluGen Inc; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 122 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 3
States / cities: Anaheim, California • DeLand, Florida • Lenexa, Kansas

Conditions: Determine Minimally to Moderately Infective Dose (MMID) of Influenza A H3N2
Interventions: Live recombinantly derived A/Bethesda/MM1/H3N2 virus; Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Influenza A H3N2, Influenza A H1N1
Interventions: FLU-IGIV, Placebo for FLU-IGIV; Biological · Other
Lead sponsor: Emergent BioSolutions; Industry
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 42
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 34 more

Conditions: Flu
Interventions: the H3N2 M2SR monovalent influenza vaccine, Placebo; Biological · Other
Lead sponsor: FluGen Inc; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: H3N2 Influenza
Interventions: Placebo, Sing2016 M2SR H3N2; Other · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 6 Months to 17 Years
Enrollment: 140 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 4
States / cities: Iowa City, Iowa • Baltimore, Maryland • Durham, North Carolina + 1 more

Conditions: Influenza
Interventions: Influenza Virus Vaccine, Monovalent A/H3N2v A/Minnesota/11/2010 NYMC X-203; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 6 Months to 17 Years
Enrollment: 270 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 8
States / cities: Atlanta, Georgia • Baltimore, Maryland • Kansas City, Missouri + 5 more

Search by objective public record fields.

Seasonal Influenza DNA Vaccine Prime With Trivalent Inactivated Vaccine (TIV) Boost Compared to TIV Alone

Influenza Challenge Study to Determine the Optimal Infection Dose and Safety of a Recombinant H3N2 (A/Texas/71/2017 (H3N2, Clade 3C3a) Influenza Strain

Pilot Influenza Challenge Study

Safety and Immunogenicity of a Monovalent Inactivated Influenza H3N2 Variant (H3N2v) Vaccine in Adult and Elderly Populations

A/Texas Flu Challenge

H3N2 M2SR in Pediatric Population

Safety and Immunogenicity of the Bris10 M2SR and Sing2016 M2SR H3N2 Monovalent Influenza Vaccines

A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age

Safety and Immunogenicity of Cam2020 M2SR H3N2 Monovalent Influenza Vaccine Alone or With Licensed IIV in Older Adults

Kinetics of the Immune Response to Inactivated Influenza Vaccine in Healthy Adults

Single Dose Texas 2017 (H3N2) Challenge Study

Effect of Age and Prior Immunity to Response to Seasonal Influenza Vaccines in Children

Safety and Immunogenicity of the Sing2016 M2SR H3N2 Monovalent Influenza Vaccine in Adults Ages 50 to 85 Years Old

Influenza A H3N2 Human Challenge Study in Healthy Adult Volunteers

Exploring Safety & Clinical Benefit of Anti-Influenza Immunoglobulin Intravenous in Hospitalized Adults With Influenza A

Safety and Immunogenicity Study of H3N2 M2SR Monovalent Influenza Vaccine in Healthy Volunteers

Assess the Safety and Immunogenicity of One or Two Doses of Sing2016 M2SR H3N2 Influenza Vaccine

Safety and Immunogenicity of a Monovalent Inactivated Influenza H3N2 Variant (H3N2v) Vaccine in Pediatric Populations